- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05453812
Meaning of Recovery After Lung Cancer Surgery
Meaning of Recovery to Patients Undergoing Lung Cancer Surgery: A Prospective Observational Study
Study Overview
Status
Conditions
Detailed Description
In patients undergoing video-assisted thoracic surgery (VATS) lung resection for lung cancer, the survey on the 'meaning of recovery after surgery' are conducted before surgery, 2 days after surgery, and 30 days after surgery. The questionnaire includes importance score of each question regarding the meaning of recovery after lung cancer surgery.
After 2 days of surgery and 30 days after surgery, the questionnaire about the recovery score and the part where the patients felt difficulties are conducted to investigate what recovery means from a patient's point of view. Length of hospital and ICU stay and postoperative complications are also evaluated.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Hojin Lee, MD
- Phone Number: 82-2072-2467
- Email: zenerdiode03@gmail.com
Study Contact Backup
- Name: Jinyoung Bae, MD
- Phone Number: 82-2072-2467
- Email: baejy88@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, KS013
- Recruiting
- Seoul National University Hospital
-
Contact:
- Hojin Lee, MD
- Phone Number: 82-2-2072-2467
- Email: zenerdiode03@gmail.com
-
Contact:
- Jinyoung Bae, MD
- Phone Number: 82-2-2072-2467
- Email: baejy88@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 19 to 80 years undergoing video-assisted thoracic surgery (VATS) lung resection for lung cancer
- Patients who can provide written consent to participate in clinical trials, understand the procedures of this clinical trial, and properly fill out patient-reported questionnaires or respond appropriately to interviews
Exclusion Criteria:
- Patients who did not consent to the trial
- Patients who have difficulty filling out questionnaires or answering interviews about the meaning of recovery
- Patients judged to be inappropriate for this clinical trial based on the opinion of the investigator or investigator
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Importance score of each question regarding the meaning of recovery after lung cancer surgery before surgery
Time Frame: 1 day before surgery
|
Importance score of each question regarding the meaning of recovery after lung cancer surgery.
The survey includes questions about returning to daily life, resolution of symptoms, overcoming mental strains, regaining independence, and enjoying life.
Each question is evaluated on a scale of 1-5, higher number means more importance to the patient.
|
1 day before surgery
|
Importance score of each question regarding the meaning of recovery after lung cancer surgery at postoperative day 2
Time Frame: postoperative day 2
|
Importance score of each question regarding the meaning of recovery after lung cancer surgery.
The survey includes questions about returning to daily life, resolution of symptoms, overcoming mental strains, regaining independence, and enjoying life.
Each question is evaluated on a scale of 1-5, higher number means more importance to the patient.
|
postoperative day 2
|
Importance score of each question regarding the meaning of recovery after lung cancer surgery at postoperative day 30
Time Frame: postoperative day 30 (between day 25 and 35)
|
Importance score of each question regarding the meaning of recovery after lung cancer surgery.
The survey includes questions about returning to daily life, resolution of symptoms, overcoming mental strains, regaining independence, and enjoying life.
Each question is evaluated on a scale of 1-5, higher number means more importance to the patient.
|
postoperative day 30 (between day 25 and 35)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recovery score (0~100 scale)
Time Frame: postoperative day 2, and postoperative day 30 (between day 25 and 35)
|
Patient self-assessed recovery score (0-100 scale, higher number means better recovery)
|
postoperative day 2, and postoperative day 30 (between day 25 and 35)
|
Recovery score evaluated with 15-item Quality of Recovery (QoR-15K) scale
Time Frame: postoperative day 2
|
Recovery score evaluated with QoR-15K scale (0-150 scale, higher number means better recovery)
|
postoperative day 2
|
Length of hospital stay (day)
Time Frame: Hospital discharge, an average of 3 days
|
Days from the end of surgery to discharge
|
Hospital discharge, an average of 3 days
|
Length of ICU stay (day)
Time Frame: ICU discharge, an average of 1 day
|
Days from the end of surgery to ICU discharge
|
ICU discharge, an average of 1 day
|
Postoperative complication
Time Frame: Postoperative day 30
|
Postoperative complication related to surgery until postoperative day 30
|
Postoperative day 30
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Recovery_lung
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States